Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (Weighted Average) (2018 - 2026)

Arcturus Therapeutics Holdings has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $28.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 4.85% year-over-year to $28.4 million; the trailing twelve-month figure through Mar 2026 stood at $28.4 million (up 4.85% YoY), and the FY2025 full-year result was $27.4 million, up 1.43% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $28.4 million, up from $27.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $28.4 million in Q1 2026, with the low at $26376.0 in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $22.2 million across 5 years, with a median of $26.9 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) plunged 99.9% — and 2023, when it surged 100578.65%.
• Arcturus Therapeutics Holdings' Shares Outstanding (Weighted Average) stood at $26.4 million in 2022, then climbed by 0.69% to $26.6 million in 2023, then gained by 1.4% to $27.0 million in 2024, then grew by 1.43% to $27.4 million in 2025, then grew by 3.78% to $28.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $28.4 million (Q1 2026), $27.4 million (Q4 2025), and $27.1 million (Q3 2025), per Business Quant data.